Inventor · disambiguated record
Yanxin Liu
Also filed as: LIU YANXIN
16 granted patents·6 pending applications·30 citations·filing 2005–2021
88Inventor score
Files withSHANGHAI FOCHON PHARMACEUTICAL CO LTD8FOCHON PHARMACEUTICALS LTD5FOCHON BIOSCIENCES LTD3CHONGQING FOCHON PHARMACEUTICAL CO LTD1INST BASIC MED SCIENCES PLA1
Top patents by PatentIndex Score
22 records- 0187US11053239B2Compounds as BLC-2-selective apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2018·Granted Jul 6, 2021·6 cites·13 claims
- 0279US7893216B2Anti-human trail receptor DR5 monoclonal antibody (AD5-10), method thereof and use of the sameINST BASIC MED SCIENCES PLA·Filed 2005·Granted Feb 22, 2011·12 cites·5 claims
- 0378US11091478B2Apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2018·Granted Aug 17, 2021·2 cites·32 claims
- 0477US9714235B2Quinazoline derivatives, compositions thereof, and use as pharmaceuticalsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2014·Granted Jul 25, 2017·3 cites·2 claims
- 0573US10087195B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2015·Granted Oct 2, 2018·2 cites·14 claims
- 0671US9556171B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2014·Granted Jan 31, 2017·2 cites·15 claims
- 0770US9725517B2Humanized monoclonal antibodies against the extracellular domain of human death receptor 5INST OF BASIC MEDICAL SCIENCES CHINESE ACAD OF MEDICAL SCIENCES·Filed 2012·Granted Aug 8, 2017·3 cites·14 claims
- 0860US12312349B2Apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2021·Granted May 27, 2025·0 cites·16 claims
- 0953US8790663B2Antigenic determinants of human death receptor DR5LIU YANXIN·Filed 2009·Granted Jul 29, 2014·0 cites·3 claims
- 1048US2023174556A1Compounds as protein kinase inhibitorsFOCHON BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 1147US10053449B2Quinazoline derivatives, compositions thereof, and use as pharmaceuticalsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2017·Granted Aug 21, 2018·0 cites·3 claims
- 1246US11723867B2Method for preparing pharmaceutical composition and pharmaceutical compositionUPM KYMMENE CORP·Filed 2020·Granted Aug 15, 2023·0 cites·17 claims
- 1346US10835535B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 17, 2020·0 cites·17 claims
- 1446US2023145305A1Compounds useful as kinase inhibitorsFOCHON BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 1545US10022374B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2016·Granted Jul 17, 2018·0 cites·13 claims
- 1645US2022235049A1SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORSFOCHON PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1740US2022041588A1Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitorsFOCHON PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1840US2006153809A1Recombinant trail vectors and uses thereofXU RUIAN·Filed 2006·Application pending·0 cites
- 1940US2015284385A1Certain dipeptidyl peptidase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 2036US11555042B2Macrocyclic compounds as TRK kinases inhibitorsFOCHON BIOSCIENCES LTD·Filed 2019·Granted Jan 17, 2023·0 cites·31 claims
- 2134US10450316B2Certain protein kinase inhibitorCHONGQING FOCHON PHARMACEUTICAL CO LTD·Filed 2016·Granted Oct 22, 2019·0 cites·16 claims
- 2233US10328060B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 25, 2019·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →